Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 402

1.

Relative and Combined Prognostic Importance of On-Treatment Mean and Visit-to-Visit Blood Pressure Variability in ONTARGET and TRANSCEND Patients.

Mancia G, Schumacher H, Böhm M, Redon J, Schmieder RE, Verdecchia P, Sleight P, Teo K, Yusuf S.

Hypertension. 2017 Nov;70(5):938-948. doi: 10.1161/HYPERTENSIONAHA.117.09714. Epub 2017 Oct 3.

PMID:
28974567
2.

Peter Joseph Wilkinson Monks.

Sleight P, Sleight V, Dawson A, Januszewski N.

BMJ. 2017 Aug 11;358:j3857. doi: 10.1136/bmj.j3857. No abstract available.

PMID:
28801305
3.

Music and the heart.

Sleight P.

Eur Heart J. 2015 Sep 14;36(35):2347. No abstract available.

PMID:
26623470
4.

Music and the heart.

Sleight P.

Eur Heart J. 2015 Jul 21;36(28):1786.

PMID:
26413596
5.

Healthy eating and reduced risk of cognitive decline: A cohort from 40 countries.

Smyth A, Dehghan M, O'Donnell M, Anderson C, Teo K, Gao P, Sleight P, Dagenais G, Probstfield JL, Mente A, Yusuf S; ONTARGET and TRANSCEND Investigators.

Neurology. 2015 Jun 2;84(22):2258-65. doi: 10.1212/WNL.0000000000001638. Epub 2015 May 6.

6.

Low resting heart rates are associated with new-onset atrial fibrillation in patients with vascular disease: results of the ONTARGET/TRANSCEND studies.

Böhm M, Schumacher H, Linz D, Reil JC, Ukena C, Lonn E, Teo K, Sliwa K, Schmieder RE, Sleight P, Yusuf S.

J Intern Med. 2015 Sep;278(3):303-12. doi: 10.1111/joim.12373. Epub 2015 Apr 29.

7.

Systolic blood pressure variation and mean heart rate is associated with cognitive dysfunction in patients with high cardiovascular risk.

Böhm M, Schumacher H, Leong D, Mancia G, Unger T, Schmieder R, Custodis F, Diener HC, Laufs U, Lonn E, Sliwa K, Teo K, Fagard R, Redon J, Sleight P, Anderson C, O'Donnell M, Yusuf S.

Hypertension. 2015 Mar;65(3):651-61. doi: 10.1161/HYPERTENSIONAHA.114.04568. Epub 2015 Jan 12.

PMID:
25583157
8.

Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials.

Cholesterol Treatment Trialists' (CTT) Collaboration, Fulcher J, O'Connell R, Voysey M, Emberson J, Blackwell L, Mihaylova B, Simes J, Collins R, Kirby A, Colhoun H, Braunwald E, La Rosa J, Pedersen TR, Tonkin A, Davis B, Sleight P, Franzosi MG, Baigent C, Keech A.

Lancet. 2015 Apr 11;385(9976):1397-405. doi: 10.1016/S0140-6736(14)61368-4. Epub 2015 Jan 9.

PMID:
25579834
9.

Resting heart rate is associated with renal disease outcomes in patients with vascular disease: results of the ONTARGET and TRANSCEND studies.

Böhm M, Schumacher H, Schmieder RE, Mann JF, Teo K, Lonn E, Sleight P, Mancia G, Linz D, Mahfoud F, Ukena C, Sliwa K, Bakris G, Yusuf S.

J Intern Med. 2015 Jul;278(1):38-49. doi: 10.1111/joim.12333. Epub 2014 Dec 22.

10.

Systolic and diastolic blood pressure changes in relation with myocardial infarction and stroke in patients with coronary artery disease.

Verdecchia P, Reboldi G, Angeli F, Trimarco B, Mancia G, Pogue J, Gao P, Sleight P, Teo K, Yusuf S.

Hypertension. 2015 Jan;65(1):108-14. doi: 10.1161/HYPERTENSIONAHA.114.04310. Epub 2014 Oct 20.

PMID:
25331850
11.

A historical perspective on peripheral reflex cardiovascular control from animals to man.

Sleight P.

Exp Physiol. 2014 Aug;99(8):1017-26. doi: 10.1113/expphysiol.2014.079434. Epub 2014 Jul 1. Review.

12.

Impact of telmisartan on cardiovascular outcome in hypertensive patients at high risk: a Telmisartan Randomised AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease subanalysis.

Foulquier S, Böhm M, Schmieder R, Sleight P, Teo K, Yusuf S, Schumacher H, Unger T.

J Hypertens. 2014 Jun;32(6):1334-41. doi: 10.1097/HJH.0000000000000154.

PMID:
24621807
13.

2013 ESH/ESC Practice Guidelines for the Management of Arterial Hypertension.

Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Böhm M, Christiaens T, Cifkova R, De Backer G, Dominiczak A, Galderisi M, Grobbee DE, Jaarsma T, Kirchhof P, Kjeldsen SE, Laurent S, Manolis AJ, Nilsson PM, Ruilope LM, Schmieder RE, Sirnes PA, Sleight P, Viigimaa M, Waeber B, Zannad F; Task Force for the Management of Arterial Hypertension of the European Society of Hypertension and the European Society of Cardiology.

Blood Press. 2014 Feb;23(1):3-16. doi: 10.3109/08037051.2014.868629. Epub 2013 Dec 20. No abstract available.

PMID:
24359485
14.

The effect of ramipril and telmisartan on serum potassium and its association with cardiovascular and renal events: results from the ONTARGET trial.

Heerspink HJ, Gao P, de Zeeuw D, Clase C, Dagenais GR, Sleight P, Lonn E, Teo KT, Yusuf S, Mann JF.

Eur J Prev Cardiol. 2014 Mar;21(3):299-309. doi: 10.1177/2047487313510678. Epub 2013 Nov 4.

PMID:
24191305
15.

Effects of nonpersistence with medication on outcomes in high-risk patients with cardiovascular disease.

Böhm M, Schumacher H, Laufs U, Sleight P, Schmieder R, Unger T, Teo K, Yusuf S.

Am Heart J. 2013 Aug;166(2):306-314.e7. doi: 10.1016/j.ahj.2013.04.016. Epub 2013 Jun 24.

PMID:
23895814
16.

Blood pressure levels for treatment of uncomplicated diabetes in primary care.

Sleight P.

J Hypertens. 2013 Aug;31(8):1527-8. doi: 10.1097/HJH.0b013e328362ff43. No abstract available.

PMID:
23822923
17.

Heart rate and blood pressure interactions in the development of erectile dysfunction in high-risk cardiovascular patients.

Kratz MT, Schumacher H, Sliwa K, Schmieder R, Pöss J, Mahfoud F, Unger T, Lonn E, Koon T, Mancia G, Sleight P, Yusuf S, Böhm M.

Eur J Prev Cardiol. 2014 Mar;21(3):272-80. doi: 10.1177/2047487313494835. Epub 2013 Jul 1. Erratum in: Eur J Prev Cardiol. 2015 Jul;22(7):950.

PMID:
23818288
18.

2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC).

Mancia G, Fagard R, Narkiewicz K, Redón J, Zanchetti A, Böhm M, Christiaens T, Cifkova R, De Backer G, Dominiczak A, Galderisi M, Grobbee DE, Jaarsma T, Kirchhof P, Kjeldsen SE, Laurent S, Manolis AJ, Nilsson PM, Ruilope LM, Schmieder RE, Sirnes PA, Sleight P, Viigimaa M, Waeber B, Zannad F; Task Force Members.

J Hypertens. 2013 Jul;31(7):1281-357. doi: 10.1097/01.hjh.0000431740.32696.cc. No abstract available.

PMID:
23817082
19.

2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC).

Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Böhm M, Christiaens T, Cifkova R, De Backer G, Dominiczak A, Galderisi M, Grobbee DE, Jaarsma T, Kirchhof P, Kjeldsen SE, Laurent S, Manolis AJ, Nilsson PM, Ruilope LM, Schmieder RE, Sirnes PA, Sleight P, Viigimaa M, Waeber B, Zannad F, Redon J, Dominiczak A, Narkiewicz K, Nilsson PM, Burnier M, Viigimaa M, Ambrosioni E, Caufield M, Coca A, Olsen MH, Schmieder RE, Tsioufis C, van de Borne P, Zamorano JL, Achenbach S, Baumgartner H, Bax JJ, Bueno H, Dean V, Deaton C, Erol C, Fagard R, Ferrari R, Hasdai D, Hoes AW, Kirchhof P, Knuuti J, Kolh P, Lancellotti P, Linhart A, Nihoyannopoulos P, Piepoli MF, Ponikowski P, Sirnes PA, Tamargo JL, Tendera M, Torbicki A, Wijns W, Windecker S, Clement DL, Coca A, Gillebert TC, Tendera M, Rosei EA, Ambrosioni E, Anker SD, Bauersachs J, Hitij JB, Caulfield M, De Buyzere M, De Geest S, Derumeaux GA, Erdine S, Farsang C, Funck-Brentano C, Gerc V, Germano G, Gielen S, Haller H, Hoes AW, Jordan J, Kahan T, Komajda M, Lovic D, Mahrholdt H, Olsen MH, Ostergren J, Parati G, Perk J, Polonia J, Popescu BA, Reiner Z, Rydén L, Sirenko Y, Stanton A, Struijker-Boudier H, Tsioufis C, van de Borne P, Vlachopoulos C, Volpe M, Wood DA.

Eur Heart J. 2013 Jul;34(28):2159-219. doi: 10.1093/eurheartj/eht151. Epub 2013 Jun 14. No abstract available.

PMID:
23771844
20.

Dual inhibition of the renin-angiotensin system in high-risk diabetes and risk for stroke and other outcomes: results of the ONTARGET trial.

Mann JF, Anderson C, Gao P, Gerstein HC, Boehm M, Rydén L, Sleight P, Teo KK, Yusuf S; ONTARGET investigators.

J Hypertens. 2013 Feb;31(2):414-21. doi: 10.1097/HJH.0b013e32835bf7b0.

PMID:
23249829
22.

Relationship between healthy diet and risk of cardiovascular disease among patients on drug therapies for secondary prevention: a prospective cohort study of 31 546 high-risk individuals from 40 countries.

Dehghan M, Mente A, Teo KK, Gao P, Sleight P, Dagenais G, Avezum A, Probstfield JL, Dans T, Yusuf S; Ongoing Telmisartan Alone and in Combination With Ramipril Global End Point Trial (ONTARGET)/Telmisartan Randomized Assessment Study in ACEI Intolerant Subjects With Cardiovascular Disease (TRANSCEND) Trial Investigators.

Circulation. 2012 Dec 4;126(23):2705-12. doi: 10.1161/CIRCULATIONAHA.112.103234.

PMID:
23212996
23.

Clinical value of baroreflex sensitivity.

La Rovere MT, Pinna GD, Maestri R, Sleight P.

Neth Heart J. 2013 Feb;21(2):61-3. doi: 10.1007/s12471-012-0349-8.

24.

Albuminuria and rapid loss of GFR and risk of new hip and pelvic fractures.

Barzilay JI, Gao P, Clase CM, Mente A, Mann JF, Sleight P, Yusuf S, Teo KK; OnTARGET/TRANSCEND Investigators.

Clin J Am Soc Nephrol. 2013 Feb;8(2):233-40. doi: 10.2215/CJN.06640712. Epub 2012 Nov 26.

25.

Ambulatory blood pressure values in the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial (ONTARGET).

Mancia G, Parati G, Bilo G, Gao P, Fagard R, Redon J, Czuriga I, Polák M, Ribeiro JM, Sanchez R, Trimarco B, Verdecchia P, van Mieghem W, Teo K, Sleight P, Yusuf S.

Hypertension. 2012 Dec;60(6):1400-6. doi: 10.1161/HYPERTENSIONAHA.112.199562. Epub 2012 Oct 15.

PMID:
23071122
26.

Alcohol consumption and the risk of incident atrial fibrillation among people with cardiovascular disease.

Liang Y, Mente A, Yusuf S, Gao P, Sleight P, Zhu J, Fagard R, Lonn E, Teo KK; ONTARGET and TRANSCEND Investigators.

CMAJ. 2012 Nov 6;184(16):E857-66. doi: 10.1503/cmaj.120412. Epub 2012 Oct 1.

27.

Impact of sex on cardiovascular outcome in patients at high cardiovascular risk: analysis of the Telmisartan Randomized Assessment Study in ACE-Intolerant Subjects With Cardiovascular Disease (TRANSCEND) and the Ongoing Telmisartan Alone and in Combination With Ramipril Global End Point Trial (ONTARGET).

Kappert K, Böhm M, Schmieder R, Schumacher H, Teo K, Yusuf S, Sleight P, Unger T; ONTARGET/TRANSCEND Investigators.

Circulation. 2012 Aug 21;126(8):934-41. doi: 10.1161/CIRCULATIONAHA.111.086660. Epub 2012 Jul 24.

PMID:
22829023
28.

Nonpharmacological treatments for hypertension.

Sleight P.

J Hypertens. 2012 Aug;30(8):1516-7. doi: 10.1097/HJH.0b013e328356d99c. No abstract available.

PMID:
22785233
29.

Influenza vaccination and major adverse vascular events in high-risk patients.

Johnstone J, Loeb M, Teo KK, Gao P, Dyal L, Liu L, Avezum A, Cardona-Munoz E, Sleight P, Fagard R, Yusuf S; Ongoing Telmisartan Alone and in Combination With Ramipril Global EndPoint Trial (ONTARGET); Telmisartan Randomized Assessment Study in ACE Intolerant Subjects With Cardiovascular Disease (TRANSCEND) Investigators.

Circulation. 2012 Jul 17;126(3):278-86. doi: 10.1161/CIRCULATIONAHA.111.071100. Epub 2012 Jun 19.

PMID:
22715472
30.

Cognitive impairment and risk of cardiovascular events and mortality.

O'Donnell M, Teo K, Gao P, Anderson C, Sleight P, Dans A, Marzona I, Bosch J, Probstfield J, Yusuf S.

Eur Heart J. 2012 Jul;33(14):1777-86. doi: 10.1093/eurheartj/ehs053. Epub 2012 May 2.

PMID:
22551598
31.

Blood pressure and other determinants of new-onset atrial fibrillation in patients at high cardiovascular risk in the Ongoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial/Telmisartan Randomized AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease studies.

Verdecchia P, Dagenais G, Healey J, Gao P, Dans AL, Chazova I, Binbrek AS, Iacobellis G, Ferreira R, Holwerda N, Karatzas N, Keltai M, Mancia G, Sleight P, Teo K, Yusuf S; Ongoing Telmisartan Alone and in Combination With Ramipril Global Endpoint TrialTelmisartan Randomized AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease Investigators.

J Hypertens. 2012 May;30(5):1004-14. doi: 10.1097/HJH.0b013e3283522a51.

PMID:
22495138
32.

Diabetes clinical trials: helped or hindered by the current shift in regulatory requirements?

Zannad F, Stough WG, Pocock SJ, Sleight P, Cushman WC, Cleland JG, McMurray JJ, Lonn E, Geller NL, Wedel H, Abadie E, Alonso-Garcia A, Pitt B.

Eur Heart J. 2012 May;33(9):1049-57. doi: 10.1093/eurheartj/ehr437. Epub 2012 Mar 15. Review.

PMID:
22422830
33.

Safety and efficacy of low blood pressures among patients with diabetes: subgroup analyses from the ONTARGET (ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial).

Redon J, Mancia G, Sleight P, Schumacher H, Gao P, Pogue J, Fagard R, Verdecchia P, Weber M, Böhm M, Williams B, Yusoff K, Teo K, Yusuf S; ONTARGET Investigators.

J Am Coll Cardiol. 2012 Jan 3;59(1):74-83. doi: 10.1016/j.jacc.2011.09.040.

34.

Urinary sodium and potassium excretion and risk of cardiovascular events.

O'Donnell MJ, Yusuf S, Mente A, Gao P, Mann JF, Teo K, McQueen M, Sleight P, Sharma AM, Dans A, Probstfield J, Schmieder RE.

JAMA. 2011 Nov 23;306(20):2229-38. doi: 10.1001/jama.2011.1729.

PMID:
22110105
35.

Blood pressure targets recommended by guidelines and incidence of cardiovascular and renal events in the Ongoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial (ONTARGET).

Mancia G, Schumacher H, Redon J, Verdecchia P, Schmieder R, Jennings G, Yusoff K, Ryden L, Liu GL, Teo K, Sleight P, Yusuf S.

Circulation. 2011 Oct 18;124(16):1727-36. doi: 10.1161/CIRCULATIONAHA.110.008870. Epub 2011 Sep 26.

PMID:
21947289
36.

The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial.

Baigent C, Landray MJ, Reith C, Emberson J, Wheeler DC, Tomson C, Wanner C, Krane V, Cass A, Craig J, Neal B, Jiang L, Hooi LS, Levin A, Agodoa L, Gaziano M, Kasiske B, Walker R, Massy ZA, Feldt-Rasmussen B, Krairittichai U, Ophascharoensuk V, Fellström B, Holdaas H, Tesar V, Wiecek A, Grobbee D, de Zeeuw D, Grönhagen-Riska C, Dasgupta T, Lewis D, Herrington W, Mafham M, Majoni W, Wallendszus K, Grimm R, Pedersen T, Tobert J, Armitage J, Baxter A, Bray C, Chen Y, Chen Z, Hill M, Knott C, Parish S, Simpson D, Sleight P, Young A, Collins R; SHARP Investigators.

Lancet. 2011 Jun 25;377(9784):2181-92. doi: 10.1016/S0140-6736(11)60739-3. Epub 2011 Jun 12.

37.

Clinical and haemodynamic correlates of heart rate turbulence as a non-invasive index of baroreflex sensitivity in chronic heart failure.

La Rovere MT, Maestri R, Pinna GD, Sleight P, Febo O.

Clin Sci (Lond). 2011 Sep;121(6):279-84. doi: 10.1042/CS20110063.

38.

Flash pulmonary oedema and bilateral renal artery stenosis: the Pickering syndrome.

Messerli FH, Bangalore S, Makani H, Rimoldi SF, Allemann Y, White CJ, Textor S, Sleight P.

Eur Heart J. 2011 Sep;32(18):2231-5. doi: 10.1093/eurheartj/ehr056. Epub 2011 Mar 15. No abstract available.

PMID:
21406441
39.

Effects of homocysteine-lowering with folic acid plus vitamin B12 vs placebo on mortality and major morbidity in myocardial infarction survivors: a randomized trial.

Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine (SEARCH) Collaborative Group, Armitage JM, Bowman L, Clarke RJ, Wallendszus K, Bulbulia R, Rahimi K, Haynes R, Parish S, Sleight P, Peto R, Collins R.

JAMA. 2010 Jun 23;303(24):2486-94. doi: 10.1001/jama.2010.840.

PMID:
20571015
40.

Erectile dysfunction predicts cardiovascular events in high-risk patients receiving telmisartan, ramipril, or both: The ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial/Telmisartan Randomized AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (ONTARGET/TRANSCEND) Trials.

Böhm M, Baumhäkel M, Teo K, Sleight P, Probstfield J, Gao P, Mann JF, Diaz R, Dagenais GR, Jennings GL, Liu L, Jansky P, Yusuf S; ONTARGET/TRANSCEND Erectile Dysfunction Substudy Investigators.

Circulation. 2010 Mar 30;121(12):1439-46. doi: 10.1161/CIRCULATIONAHA.109.864199. Epub 2010 Mar 15.

PMID:
20231536
41.

Effects of telmisartan, ramipril, and their combination on left ventricular hypertrophy in individuals at high vascular risk in the Ongoing Telmisartan Alone and in Combination With Ramipril Global End Point Trial and the Telmisartan Randomized Assessment Study in ACE Intolerant Subjects With Cardiovascular Disease.

Verdecchia P, Sleight P, Mancia G, Fagard R, Trimarco B, Schmieder RE, Kim JH, Jennings G, Jansky P, Chen JH, Liu L, Gao P, Probstfield J, Teo K, Yusuf S; ONTARGET/TRANSCEND Investigators.

Circulation. 2009 Oct 6;120(14):1380-9. doi: 10.1161/CIRCULATIONAHA.109.865774. Epub 2009 Sep 21.

PMID:
19770395
42.

Clinical evidence from ONTARGET: the value of an angiotensin II receptor blocker and an angiotensin-converting enzyme inhibitor.

Sleight P.

J Hypertens Suppl. 2009 Jul;27(5):S23-9. doi: 10.1097/01.hjh.0000357905.78704.9a.

PMID:
19587551
43.

Long-term time-course of nocturnal breathing disorders in heart failure patients.

Pinna GD, Maestri R, Mortara A, Johnson P, Andrews D, Ponikowski P, Witkowski T, La Rovere MT, Sleight P.

Eur Respir J. 2010 Feb;35(2):361-7. doi: 10.1183/09031936.00066709. Epub 2009 Jul 2.

44.

Dynamic interactions between musical, cardiovascular, and cerebral rhythms in humans.

Bernardi L, Porta C, Casucci G, Balsamo R, Bernardi NF, Fogari R, Sleight P.

Circulation. 2009 Jun 30;119(25):3171-80.

PMID:
19569263
45.

The joint effects of apolipoprotein B, apolipoprotein A1, LDL cholesterol, and HDL cholesterol on risk: 3510 cases of acute myocardial infarction and 9805 controls.

Parish S, Peto R, Palmer A, Clarke R, Lewington S, Offer A, Whitlock G, Clark S, Youngman L, Sleight P, Collins R; International Studies of Infarct Survival Collaborators.

Eur Heart J. 2009 Sep;30(17):2137-46. doi: 10.1093/eurheartj/ehp221. Epub 2009 Jun 11.

46.

Prognostic value of blood pressure in patients with high vascular risk in the Ongoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial study.

Sleight P, Redon J, Verdecchia P, Mancia G, Gao P, Fagard R, Schumacher H, Weber M, Böhm M, Williams B, Pogue J, Koon T, Yusuf S; ONTARGET investigators.

J Hypertens. 2009 Jul;27(7):1360-9. doi: 10.1097/HJH.0b013e32832d7370.

PMID:
19506526
47.

Home telemonitoring in heart failure patients: the HHH study (Home or Hospital in Heart Failure).

Mortara A, Pinna GD, Johnson P, Maestri R, Capomolla S, La Rovere MT, Ponikowski P, Tavazzi L, Sleight P; HHH Investigators.

Eur J Heart Fail. 2009 Mar;11(3):312-8. doi: 10.1093/eurjhf/hfp022.

48.

Pathophysiological and clinical relevance of simplified monitoring of nocturnal breathing disorders in heart failure patients.

Pinna GD, Maestri R, Mortara A, Johnson P, Andrews D, Ponikowski P, Witkowski T, Robbi E, La Rovere MT, Sleight P.

Eur J Heart Fail. 2009 Mar;11(3):264-72. doi: 10.1093/eurjhf/hfp006. Epub 2009 Feb 3.

49.

Glucose intolerance and diabetes as risk factors for cognitive impairment in people at high cardiovascular risk: results from the ONTARGET/TRANSCEND research programme.

Cukierman-Yaffe T, Gerstein HC, Anderson C, Zhao F, Sleight P, Hilbrich L, Jackson SH, Yusuf S, Teo K; ONTARGET/TRANSCEND Investigators.

Diabetes Res Clin Pract. 2009 Mar;83(3):387-93. doi: 10.1016/j.diabres.2008.12.005. Epub 2009 Jan 20.

PMID:
19157618
50.

Prognostic implications of baroreflex sensitivity in heart failure patients in the beta-blocking era.

La Rovere MT, Pinna GD, Maestri R, Robbi E, Caporotondi A, Guazzotti G, Sleight P, Febo O.

J Am Coll Cardiol. 2009 Jan 13;53(2):193-9. doi: 10.1016/j.jacc.2008.09.034.

Supplemental Content

Loading ...
Support Center